Relapsed Hodgkin's lymphoma:: Immunostaining patterns in relation to survival

被引:6
作者
Amini, RM [1 ]
Enblad, G [1 ]
Engström, P [1 ]
Christensson, B [1 ]
Glimelius, B [1 ]
Sundström, C [1 ]
机构
[1] Uppsala Univ, Dept Genet & Pathol, Akad Sjukhuset, S-75185 Uppsala, Sweden
关键词
Hodgkin's lymphoma; immunohistochemistry; outcome; p53; Rb; relapse;
D O I
10.1080/10428190290026303
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with relapsing Hodgkin's lymphoma (HL) have a rather poor prognosis and mechanisms that lead to resistance to therapy are poorly understood. Our aims were to investigate the immunohistochemical staining patterns of Rb (retinoblastoma protein) and the p53 tumour suppressor protein in HL at initial presentation and at relapse in order to elucidate a possible role in disease progression and resistance to therapy. Further to evaluate the presence and prognostic importance of Epstein-Barr virus (EBV) and anaplastic lymphoma kinase (ALK). Eighty-one cases of relapsing HL were reexamined histopathologically and immunostained for the expression of p53, Rb, ALK and CD30. EBV was detected with LMP-1 stainings and in situ hybridisation for EBER. Clinical data were extracted from the Swedish National Health Care Programme for HL. Median follow-up time was six years (range 0-12) from the date of relapse. The majority of cases were positive for p53 and Rb both at presentation and at relapse, though to a different extent. Both an increase and a decrease in the proportion of stained turnout cells were observed. None of our cases was ALK-positive and 44% were EBV-positive. No specific staining pattern was directly correlated to survival. In 12 patients a switch in HL subtype from diagnosis to relapse was observed and the five-year Hodgkin-specific survival (HLS) was statistically significantly inferior, 37 vs 81% (p = 0.002), in those patients. We found a significant relation between the expression of p53 and EBV at diagnosis and relapse, indicating a clonal relationship. We were unable to find any specific staining pattern of p53 or Rb, affecting survival.
引用
收藏
页码:1253 / 1260
页数:8
相关论文
共 31 条
[1]  
Amini RM, 1997, INT J CANCER, V71, P510, DOI 10.1002/(SICI)1097-0215(19970516)71:4<510::AID-IJC2>3.3.CO
[2]  
2-P
[3]  
BOIOCCHI M, 1993, AM J PATHOL, V142, P33
[4]   Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [J].
Bonfante, V ;
Santoro, A ;
Viviani, S ;
Devizzi, L ;
Balzarotti, M ;
Soncini, F ;
Zanini, M ;
Valagussa, P ;
Bonadonna, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :528-534
[5]   A systematic overview of chemotherapy effects in Hodgkin's disease [J].
Brandt, L ;
Kimby, E ;
Nygren, P ;
Glimelius, B .
ACTA ONCOLOGICA, 2001, 40 (2-3) :185-197
[6]  
Brink AATP, 1998, MODERN PATHOL, V11, P376
[7]   THE RETINOBLASTOMA PROTEIN IS PHOSPHORYLATED DURING SPECIFIC PHASES OF THE CELL-CYCLE [J].
BUCHKOVICH, K ;
DUFFY, LA ;
HARLOW, E .
CELL, 1989, 58 (06) :1097-1105
[8]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[9]   Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population [J].
Enblad, G ;
Sandvej, K ;
Sundström, C ;
Pallesen, G ;
Glimelius, B .
ACTA ONCOLOGICA, 1999, 38 (04) :425-429
[10]   Treatment of Hodgkin's disease: The Swedish national care programme experience [J].
Glimelius, B ;
Enblad, G ;
Kalkner, M ;
Gustavsson, A ;
Jakobsson, M ;
Branehog, I ;
Lenner, P ;
Bjorkholm, M .
LEUKEMIA & LYMPHOMA, 1996, 21 (1-2) :71-78